|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Terns Pharmaceuticals, Inc. (TERN) |
|
|
$6.01 0.00 (0.00%) as of 4:30 Fri 5/31
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
64,880,000 |
Market
Cap: |
389.93(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$3.37 - $12.48 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address diseases, such as non-alcoholic steatohepatitis (NASH) and obesity. Co.'s primary program is TERN-101, a liver-distributed, non-bile acid Farnesoid X Receptor (FXR) agonist that has demonstrated sustained liver FXR activation, as well as a favorable tolerability profile across multiple clinical trials. Co.'s another clinical stage program, TERN-201, is an inhibitor of Vascular Adhesion Protein-1. Co. is also evaluating the potential to co-administer TERN-201 in combination with a metabolically active NASH treatment.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,486 |
14,886,560 |
Total Buy Value |
$0 |
$0 |
$5,618 |
$43,676,884 |
Total People Bought |
0 |
0 |
2 |
7 |
Total Buy Transactions |
0 |
0 |
2 |
21 |
Total Shares Sold |
420,663 |
420,663 |
420,663 |
1,920,663 |
Total Sell Value |
$2,796,859 |
$2,796,859 |
$2,796,859 |
$11,046,859 |
Total People Sold |
1 |
1 |
1 |
2 |
Total Sell Transactions |
3 |
3 |
3 |
4 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Vivo Capital Surplus Fund Viii, L.p. |
10% Owner |
|
2024-04-03 |
4 |
AS |
$6.20 |
$856,009 |
I/I |
(138,066) |
268,573 |
|
0% |
|
Vivo Capital Surplus Fund Viii, L.p. |
10% Owner |
|
2024-04-02 |
4 |
AS |
$6.65 |
$674,842 |
I/I |
(101,480) |
272,722 |
|
-9% |
|
Vivo Capital Surplus Fund Viii, L.p. |
10% Owner |
|
2024-04-01 |
4 |
AS |
$6.99 |
$1,266,008 |
I/I |
(181,117) |
275,772 |
|
-15% |
|
Kuriakose Emil |
Chief Medical Officer |
|
2024-03-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
58,750 |
|
-19% |
|
Quigley Jill M. |
Sr. Advisor & Strategy Officer |
|
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
30,000 |
|
- |
|
Quirk Erin |
President, Head of R&D |
|
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
75,000 |
|
- |
|
Vignola Mark J. |
Chief Financial Officer |
|
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
68,750 |
87,149 |
|
- |
|
Yoon Seokho Bryan |
COO and General Counsel |
|
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
68,750 |
87,149 |
|
- |
|
Vignola Mark J. |
Chief Financial Officer |
|
2023-11-30 |
4 |
B |
$3.78 |
$2,809 |
D/D |
743 |
18,399 |
0.01 |
17% |
|
Yoon Seokho Bryan |
COO and General Counsel |
|
2023-11-30 |
4 |
B |
$3.78 |
$2,809 |
D/D |
743 |
18,399 |
0.01 |
17% |
|
Quigley Jill M. |
Sr. Advisor & Strategy Officer |
|
2023-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
Yoon Seokho Bryan |
COO and General Counsel |
|
2023-05-31 |
4 |
B |
$1.41 |
$14,096 |
D/D |
9,997 |
17,656 |
0.01 |
-50% |
|
Sundaram Senthil Vel |
Chief Executive Officer |
|
2023-05-31 |
4 |
B |
$1.41 |
$2,977 |
D/D |
2,111 |
9,770 |
0.01 |
-50% |
|
Vignola Mark J. |
Chief Financial Officer |
|
2023-05-31 |
4 |
B |
$1.41 |
$14,096 |
D/D |
9,997 |
17,656 |
0.01 |
-50% |
|
Gordon Carl L |
Director |
|
2022-12-23 |
4 |
B |
$7.25 |
$1,000,000 |
I/I |
137,931 |
4,882,854 |
2.25 |
51% |
|
Orbimed Genesis Gp Llc |
Director |
|
2022-12-23 |
4 |
B |
$7.25 |
$1,000,000 |
I/I |
137,931 |
4,882,854 |
2.25 |
51% |
|
Lu Hongbo |
|
|
2022-12-23 |
4 |
B |
$7.25 |
$5,499,995 |
I/I |
758,620 |
4,340,212 |
0.01 |
51% |
|
Yoon Seokho Bryan |
COO and General Counsel |
|
2022-11-30 |
4 |
B |
$1.41 |
$4 |
D/D |
3 |
7,659 |
0.01 |
57% |
|
Sundaram Senthil Vel |
Chief Executive Officer |
|
2022-11-30 |
4 |
B |
$1.41 |
$4 |
D/D |
3 |
7,659 |
0.01 |
57% |
|
Vignola Mark J. |
Chief Financial Officer |
|
2022-11-30 |
4 |
B |
$1.41 |
$4 |
D/D |
3 |
7,659 |
0.01 |
57% |
|
Oriental Spring Venture Ltd |
10% Owner |
|
2022-11-23 |
4 |
S |
$5.50 |
$8,250,000 |
I/I |
(1,500,000) |
529,762 |
|
-97% |
|
Vivo Capital Surplus Fund Viii, L.p. |
10% Owner |
|
2022-09-07 |
4 |
B |
$3.60 |
$2,160,000 |
I/I |
600,000 |
3,581,592 |
1.5 |
120% |
|
Lu Hongbo |
|
|
2022-09-07 |
4 |
B |
$3.60 |
$2,160,000 |
I/I |
600,000 |
3,581,592 |
0.01 |
120% |
|
Gordon Carl L |
Director |
|
2022-08-16 |
4 |
B |
$2.42 |
$8,929,800 |
I/I |
3,690,000 |
762,400 |
2.25 |
84% |
|
Orbimed Genesis Gp Llc |
Director |
|
2022-08-16 |
4 |
B |
$2.42 |
$8,929,800 |
I/I |
3,690,000 |
762,400 |
2.25 |
84% |
|
44 Records found
|
|
Page 1 of 2 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|